Back to Search Start Over

Sesquiterpene lactones improve secretory diarrhea symptoms by inhibiting intestinal Ca 2+ -activated Cl - channel activities directly and indirectly.

Authors :
Qu C
Guan X
Li C
Zhu X
Ma T
Li H
Yu B
Yang H
Source :
European journal of pharmacology [Eur J Pharmacol] 2023 Sep 15; Vol. 955, pp. 175917. Date of Electronic Publication: 2023 Jul 18.
Publication Year :
2023

Abstract

Secretory diarrhea caused by bacteria and viruses is usually accompanied by activation of the cystic fibrosis transmembrane conductance regulator (CFTR) and calcium-activated Cl <superscript>-</superscript> channels (CaCCs) in the intestinal epithelium. Inhibition of CFTR and CaCCs activities significantly reduces fluid losses and intestinal motility in diarrheal diseases. For this reason, CFTR and CaCCs are potential targets of therapeutic drug screening. Here, we reported that the sesquiterpene lactones, alantolactone (AL) and isoalantolactone (iAL), significantly inhibited ATP and E <subscript>act</subscript> -induced short-circuit currents in T84, HT-29 and Fischer rat thyroid (FRT) cells expressing transmembrane protein 16A (TMEM16A) in a concentration-dependent manner. AL and iAL also inhibited the CaCC-mediated short-circuit currents induced by carbachol in the mouse colons. Both compounds inhibited forskolin-induced currents in T84 cells but did not significantly affect mouse colons. In vivo studies indicated that AL and iAL attenuated gastrointestinal motility and decreased watery diarrhea in rotavirus-infected neonatal mice. Preliminary mechanism studies showed that AL and iAL inhibited CaCCs at least partially by inhibiting Ca <superscript>2+</superscript> release and basolateral membrane K <superscript>+</superscript> channels activity. These findings suggest a new pharmacological activity of sesquiterpene lactone compounds that might lead to the development of treatments for rotaviral secretory diarrhea.<br />Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2023 Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
1879-0712
Volume :
955
Database :
MEDLINE
Journal :
European journal of pharmacology
Publication Type :
Academic Journal
Accession number :
37473982
Full Text :
https://doi.org/10.1016/j.ejphar.2023.175917